Centocor reports Remicade data
Johnson & Johnson (JNJ) subsidiary Centocor said that in an investigator-run Belgian study of its Remicade infliximab to treat 40 patients with spondyloarthropathies (SpA), the Remicade group showed improvement on the primary endpoint of patient and physician global assessment of disease activity compared to no improvement for placebo patients at 12 weeks.
Separately, data from an investigator-run German trial of 70 patients with ankylosing spondylitis showed that 53% of Remicade patients responded, as measured by a 50% improvement in Bath AS disease activity index (the primary endpoint), compared to 9% of placebo patients. Remicade is an anti-TNF chimeric monoclonal antibody marketed to treat rheumatoid arthritis and Crohn's disease. Data were presented at the American College of Rheumatology meeting in San Francisco. ...